Method of Diagnosing Breast Carcinoma

Simple SummaryContent extracted from patent full text and abstract with AI.

This invention describes new methods for diagnosing, prognosing, and monitoring the treatment of breast carcinoma by measuring the levels of specific markers, Calponin-h2 (CNN-2) and Calmodulin-like protein 5 (CALML5), in biological samples such as blood, serum, plasma, saliva, or tissue. Elevated levels of these proteins indicate the presence of breast cancer and their levels can also predict disease prognosis and monitor the effectiveness of breast cancer therapy. The invention includes diagnostic kits and marker panels for these purposes, allowing the assays to be performed with common laboratory techniques such as ELISA, PCR, or Western Blot.

Use CasesContent extracted from patent full text and abstract with AI.

• Screening and early diagnosis of breast cancer using minimally invasive blood or serum tests.
• Prognosis prediction in patients already diagnosed with breast carcinoma, supporting clinical decision-making.
• Monitoring and evaluating the effectiveness of breast cancer treatments by tracking marker levels over time.
• Providing point-of-care or local laboratory breast cancer tests, especially in regions lacking access to mammography facilities.
• Enriching multi-marker panels for improved accuracy of breast cancer diagnostics and monitoring.

BenefitsContent extracted from patent full text and abstract with AI.

• Non-invasive or minimally invasive testing using common body fluids such as blood or saliva, reducing patient discomfort and risk.
• Faster and potentially more frequent assessment of cancer status compared to imaging, enabling better disease management and treatment adjustments.
• Improved accuracy in diagnosing breast carcinoma versus traditional methods, especially in younger women or those with dense breast tissue where mammography is less reliable.
• Cost-effective approach, as the tests use widely available laboratory techniques and can be performed by any qualified healthcare professional.
• Potential for integration into multiplexed assays, combining Calponin-h2 and CALML5 with other breast cancer markers to further enhance diagnostic and prognostic performance.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to methods of diagnosing a breast carcinoma, determining the prognosis of a patient diagnosed with breast carcinoma and determining the efficacy of a treatment regimen of breast carcinoma in a patient, using Calponin-h2 and /or CALML 5 as markers. Furthermore, the invention relates to a kit and a marker panel for use in these methods.